Searchable abstracts of presentations at key conferences on calcified tissues

ba0005p65 | Bone development/growth and fracture repair | ECTS2016

Effect of postponing puberty and cross-sex hormone therapy on bone turnover markers and BMAD in transgender adolescents

Vlot Mariska , Klink Daniel , den Heijer Martin , Blankenstein Marinus , Rotteveel Joost , Heijboer Annemieke

Background: Puberty is highly important for the accumulation of bone mass. Bone turnover and bone mineral density can be affected in transgender adolescents when puberty is postponed by gonadotropin-releasing hormone analogues (GnRHa), followed by treatment with cross-sex hormone therapy (CSHT).Objective: To investigate the effect of GnRHa and CSHT on bone turnover markers (BTMs) and bone mineral apparent density (BMAD) in transgender adolescents.<p ...

ba0004p150 | (1) | ICCBH2015

Impaired bone mineral density in adult survivors of childhood cancer: a literature review

Pluijm Saskia , Marissa den Hoed , Neggers Sebastian , Pieters Rob , den Heuvel-Eibrink Marryvan

Objectives: impairment of bone mineral density (BMD) is a complication of childhood cancer treatment. A comprehensive review on the occurrence of impaired BMD in childhood cancer survivors (CCS), and which disease subgroups are at risk has never been pursued so far. The aim of this study was to summarize all knowledge on BMD status and associated determinants in long-term adult childhood cancer survivors (CCS) based on available literature.Methods: an el...

ba0004p83 | (1) | ICCBH2015

RANKL, OPG, Dkk1 in Duchenne muscular dystrophy

Broggi Francesca , Vai Silvia , Morandi Lucia , Gorni Ksenija , D'Angelo Grazia , Pane Marika , Bianchi Maria Luisa

Low bone mineral density (BMD) and an increased rate of both peripheral and vertebral fractures have been observed in patients with Duchenne muscular dystrophy (DMD). However, studies specifically addressing bone metabolism, BMD and fractures in this disease are still very few.Our ongoing multicenter, prospective study is aimed to identify the characteristics of the DMD boys with a higher risk of bone loss and fractures, through the evaluation of bone tu...

ba0005oc5.6 | Risk factors for fracture, Pagets disease of bone and musle and bone | ECTS2016

The metabolic alterations behind bone fragility in Duchenne muscular dystrophy

Broggi Francesca , Vai Silvia , Maggi Lorenzo , Gorni Ksenija , D'Angelo Grazia , Pane Marika , Bianchi Maria Luisa

Low bone mineral density (BMD) and an increased rate of both peripheral and vertebral fractures have been observed in patients with Duchenne muscular dystrophy (DMD), but studies on bone metabolic alterations in this disease are still very few.We are now presenting the preliminary findings of an ongoing multicenter, prospective study aimed to identify the characteristics of DMD boys carrying a higher risk of bone loss and fractures, through the evaluatio...

ba0006p053 | (1) | ICCBH2017

Determinants of bone density in Duchenne muscular dystrophy

Broggi Francesca , Vai Silvia , Baranello Giovanni , Gorni Ksenja , D'Angelo Grazia , Pane Marika , Vita Gianluca , Bianchi Maria Luisa

Objectives: Low bone mineral density (BMD) and increased frequency of peripheral and vertebral fractures have been reported in boys with Duchenne muscular dystrophy (DMD), but studies on the determinants of low BMD are still very few. We are currently carrying out a multicenter, prospective study aimed to identify the characteristics of DMD boys with a higher risk of bone loss and fractures.Methods: Forty-two DMD boys (mean age 9.9±3.3 years) underw...

ba0007p28 | (1) | ICCBH2019

Duchenne muscular dystrophy: preliminary results of the Risbo-DMD study

Broggi Francesca , Vai Silvia , Baranello Giovanni , Sansone Valeria Sansone , D'Angelo Grazia , Pane Marika , Vita Gianluca , Bianchi Maria Luisa

Introduction: Reduced bone mineral density [BMD] and increased fracture risk are common complications in all conditions characterized by severely reduced physical activity and/or requiring long-term glucocorticoid [GC] treatment, including Duchenne Muscular Dystrophy [DMD].Objectives: The RisBo-DMD study (EudraCT 2011-005745-12) is a 24-month prospective multicenter study, aimed at identifying DMD patients at higher risk of fractures and improving the bo...

ba0002p36 | (1) | ICCBH2013

Vitamin D deficiency and its relationship to parathyroid hormone in morbidly obese adolescents prior to bariatric surgery

Censani Marisa , Stein Emily , Shane Elizabeth , Oberfield Sharon , McMahon Donald , Lerner Shulamit , Fennoy Ilene

Objectives: Obese adults commonly have vitamin D deficiency and secondary hyperparathyroidism prior to bariatric surgery. Whether similar metabolic abnormalities exist in morbidly obese adolescents is not known. This study investigated the prevalence of vitamin D deficiency and evaluated the relationship between vitamin D and parathyroid hormone (PTH) in morbidly obese adolescents undergoing evaluation for bariatric surgery.Methods: A cross-sectional stu...

ba0007p151 | (1) | ICCBH2019

The safety and efficacy of denosumab versus zoledronic acid in the treatment of pediatric osteoporosis: a randomized controlled pilot trial

Robinson Marie-Eve , Ma Jinhui , Khan Nasrin , Khatchadourian Karine , Page Marika , Konji Victor , Ann Matzinger Mary , Shenouda Nazih , Jaremko Jacob L , Zuijdwijk Caroline , Jackowski Stefan , Saleh David , MacLeay Lynn , Siminoski Kerry , Ward Leanne M

Objectives: Denosumab (Dmab) is a monoclonal antibody targeting RANKL administered by sub-cutaneous injection. Given its convenient mode of administration, our goal was to assess the safety and efficacy of Dmab compared to intravenous zoledronic acid (ZA) in pediatric osteoporosis.Methods: In this one-year pilot study (NCT02632916), children 4–16 years with low-trauma fractures due to osteoporosis were randomized 1:1 to receive ZA 0.025 mg/kg or Dma...

ba0007p152 | (1) | ICCBH2019

An evaluation of the rebound phenomenon during denosumab therapy in children with low turnover osteoporosis

Robinson Marie-Eve , Ma Jinhui , Khan Nasrin , Khatchadourian Karine , Page Marika , Konji Victor , Ann Matzinger Mary , Shenouda Nazih , Jaremko Jacob L , Zuijdwijk Caroline , Jackowski Stefan , Saleh David , MacLeay Lynn , Siminoski Kerry , Ward Leanne M

Objectives: Denosumab (Dmab) is a monoclonal antibody targeting RANKL administered by sub-cutaneous injection. Recent reports have raised concern about the ‘rebound phenomenon’ (hypercalcemia and increases in bone turnover markers, BTM) following Dmab in adults, and during treatment in children with osteogenesis imperfecta. The purpose of this report was to explore this phenomenon in children with osteoporosis associated with lower bone turnover.<p class="abstext...